Kiromic Dual Core Technology

Our approach to oncology is based on the streamlined combination of our Biomarker Lead Antigen Discovery Engine (BLADE) platform and our ground-breaking Systemic Multi-Antigen Reprogrammed T-cell (SMART) activation technology. This dual core technology allows Kiromic to uniquely integrate and optimize the two main steps in the design of cancer immunotherapies: 1) the discovery and validation of immunotargets (BLADE), and 2) the safe and effective activation of the immune system by specifically reprogramming T-cells against cancer (SMART).
Kiromic Technology